This session will begin with a presentation from the HSBC Innovation Banking 2023 annual report. The report shows investment pace similar to 2H 2022, with crossovers returning to lead later-stage deals in 2H 2023. While Series B means “Be in the clinic” there still is a small opening for strong pre-clinical stories to get funded. Corporates, growth/traditional VCs, and sovereign wealth join crossovers to create a (smaller than 2021 but) still healthy group of investors willing to put new capital to work. After the overview, investors and executives will discuss venture and alternative financing opportunities in 2024 as companies seek to continue development of important therapies.